Abstracts tagged "autoimmune diseases"

Abstract Number: 2594 • ACR Convergence 2024
A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways
Saul Kivimae¹, Sandip Mukherjee², Phi Quach³, Rhoneil Pena⁴, Olga Zemska³, Michal Olszewski⁵, Jicai Huang³, Michael Labson⁶, Donald Walker¹, Mekhala Maiti⁷, Chakrapani Tripathi⁸, Thomas Chang³, Suresh Adapala⁹, Damon Hamel³, Katherine Brendza³, Takahiro Miyazaki³ and Jonathan Zalevsky¹, ¹Nektar Therapeutics, San Francisco, CA, ²Nurix Therapeutics, San Francisco, ³Nektar Therapeutics, San Francisco, ⁴Sutro Biopharma, South San Francisco, ⁵Vaxcyte, San Francisco, ⁶Guardant Health, Palo Alto, ⁷Alumis, Inc, South San Francisco, ⁸Theragent Inc, Arcadia, CA, ⁹Inotiv, Rockville, MD
Background/Purpose: Current standard of care chronic inflammatory disease therapies are designed to suppress inflammation and are not optimized for inflammation resolution and restoration of tissue…
Abstract Number: PP11 • ACR Convergence 2024
Living Well with Chronic Illness: Decades with MCTD
Carol KAMINSKI, HP (Hewlett Packard) Retired, Wilmington, NC
Background/Purpose: In the fall of 1985, I was not feeling well. I attributed my tiredness, weakness and malaise to stress and carried on. Walking upstairs I…
Abstract Number: 0014 • ACR Convergence 2024
Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease
Kaiyuan Zi and Juan Liang, GemPharmatech, San Diego
Background/Purpose: The etiology of IgA nephropathy (IgAN) remains only partly understood, but the presence of IgA antibodies together with the myeloid IgA-receptor FcαRI/CD89 complexes in…
Abstract Number: 0138 • ACR Convergence 2024
SARS-CoV-2 Vaccine Acceptance, Hesitancy and Uptake in a Cohort of Patients with Inflammatory Rheumatic Diseases (IRD)
iulia roman¹, Xenofon Baraliakos², Uta Kiltz³, Juergen Braun⁴ and Ioana Andreica⁵, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Vaccine acceptance is important to achieve high vaccination coverage and possibly herd immunity. Related to the evolution of the SARS-CoV-2 pandemic with its socio-political…
Abstract Number: 0288 • ACR Convergence 2024
Hypersensitivity Pneumonitis with Autoimmune Features: A New Entity?
Pol Maymó¹, Javier Narvaez-García², Guadalupe Bermudo¹, Vanesa Vicens-Zygmunt³, Santiago Bolivar⁴, Belen del Río⁵, Judith Palacios⁵, Martí Aguilar Coll², Monserrat Roig Kim², Laia De Daniel², Paola Vidal¹, Joan Miquel Nolla² and María Molina¹, ¹Hospital Universtiario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain, ⁵Hospital Universtiario de Bellvitge, Hosptalet de Llobregat, Catalonia, Spain
Background/Purpose: Hypersensitivity pneumonitis (HP) is an interstitial lung disease induced by inhaled antigens that trigger an interstitial and bronchoalveolar lymphocytic inflammatory response. This immune response…
Abstract Number: 0366 • ACR Convergence 2024
Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study
Koushan Kouranloo¹ and Chris Wincup², ¹Internal Medicine Resident., London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Clinicians are encouraged to consider patient preferences for offering face-to-face vs virtual consultations. This adaptability is particularly important to rheumatologists caring for patients with…
Abstract Number: 0570 • ACR Convergence 2024
Prevalence of Comorbidities and Racial Disparities in Anterior Uveitis Risk Among Ankylosing Spondylitis Patients
Halah Alfatlawi¹, abdulmajeed alharbi², eun seo kwak², rawnag el sheikh² and nezam altorok², ¹the university of toledo, Toledo, OH, ²the university of toledo, Toledo
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial spine, commonly associated with extra-articular manifestations such as anterior uveitis (AU). Racial…
Abstract Number: 0778 • ACR Convergence 2024
Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease
Justin Chou¹, Ricardo Grieshaber-Bouyer², Michelle J Wu³, Christina Bergmann², Jule Taubmann⁴, Fabian Müller⁵, Aline Bozec⁴, Tobias Rothe², Andreas MAckensen⁶, Amber Podoll⁷, Jonathan Gutman⁷, Aiden Haghikia⁸, Dimitrios Mougiakakos⁹, Gary Tong³, Pouya Kheradpour³, Francis Kim¹⁰, Prameela Ramesan¹⁰, Brandon Kwong¹⁰, Kunbin Qu¹⁰, Bishwa Ganguly¹⁰, Dominic Borie¹⁰, James Chung¹⁰ and Georg Schett¹¹, ¹Kyverna Therapeutics, Emeryville, CA, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Verily Life Sciences, South San Francisco, CA, ⁴Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁶Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁷University of Colorado Anschutz Medical Campus, Aurora, CO, ⁸Otto-von-Guericke University, Magdeburg, Germany, ⁹Otto-von-Guericke University, Magdeburg, Germany, Magdeburg, Germany, ¹⁰Kyverna Therapeutics, Inc., Emeryville, CA, ¹¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy represents a promising advancement in the treatment of autoimmune diseases, including systemic sclerosis (SSc), idiopathic inflammatory myopathy…
Abstract Number: 0879 • ACR Convergence 2024
A Novel, Oral, Allosteric Inhibitor of Tyrosine Kinase 2 (TYK2) Demonstrates In Vitro Potency, Selectivity, and In Vivo Efficacy in Mouse Models of Psoriasis
Razika Hussein¹, Pamela Tsuruda¹, Shahab Mortezaei¹, Nicky Ferdyan¹, Christopher Wegerski², Karthik Srinivasan¹, Gavin Hirst¹ and Neelufar Mozaffarian¹, ¹Atomwise Inc., San Francisco, ²Atomwise Inc., San Francisco, CA
Background/Purpose: Tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family, plays a key role in several inflammatory diseases. Orthosteric, small molecule inhibitors…
Abstract Number: 0966 • ACR Convergence 2024
CDDO-Me Attenuates Pro-fibrotic Activation in Macrophages and Fibroblasts in Systemic Sclerosis
Heetaek Yang¹, Chanhyuk Park², Chen-Yu Wang³, Emily Morris⁴, Karen Liby⁵, Michael Whitfield⁶ and Patricia Pioli², ¹Dartmouth College, West Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth College, Lebanon, NH, ⁴Dartmouth College, Enfield, NH, ⁵Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, ⁶Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is characterized by dysfunctional immune activation, oxidative stress, and fibrosis. In prior work, we have shown that SSc macrophages (MØs) have…
Abstract Number: 1117 • ACR Convergence 2024
JAK Inhibitor Therapy in Refractory Uveitis Due to Immune-mediated Inflammatory Disorders. Multicenter Study and Literature Review
Nuria Barroso Garcia¹, Lara Sanchez Bilbao², Jose Luis Martin Varillas³, Vanesa Calvo-Rio⁴, Mar Esteban Ortega⁵, Santiago muñoz Fernández⁵, Jose Luis álvarez Vega⁶, Emma Beltran Catalan⁷, Vega Jovani⁸, Olga Maiz Alonso⁹, Raúl Veroz González¹⁰, Carmen Alvarez Reguera¹¹, Rosalia Demetrio Pablo¹² and Ricardo Blanco-Alonso¹³, ¹Rheumatology, Hospital Regional Universitario, Universidad de Málaga UMA, Málaga, Spain, Malaga, Spain, ²Rheumatology and Ophthalmology. Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology. Hospital de Laredo. IDIVAL, Immunopathology Group. Laredo, Spain, Santander, Spain, ⁴Valdecilla Hospital, Santander, Cantabria, Spain, ⁵Rheumatology and Ophthalmology. Hospital Infanta Sofía, Madrid. Spain, Madrid, Spain, ⁶Rheumatology. Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, Badajoz, Spain, ⁷Rheumatology. Hospital del Mar. Barcelona, Spain, Barcelona, Spain, ⁸National Health system, Alicante, Spain, ⁹Rheumatology. Hospital de Donostia. San Sebastián, Spain, San Sebastián, Spain, ¹⁰Hospital Mérida, Badajoz, Spain, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²Rheumatology and Ophthalmology. Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology Group. Santander. Spain, Santander, Spain, ¹³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Non-infectious uveitis refractory to conventional immunosuppressants and even biologic therapy can lead to severe ocular conditions. Janus Kinase inhibitors (JAKINIBs) appear to be effective…
Abstract Number: 1372 • ACR Convergence 2024
Upadacitinib and Other JAK Inhibitors in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study Clinical Practice.
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesús Loarce³, Leticia del Olmo Perez⁴, Sara García-Pérez⁵, Guillermo Gonzalez Mozo de Rosales⁶, José Rosas-Gómez de Salazar⁷, Ana Urruticoechea-Arana⁸, Andrea García-Valle⁹, Juan Moreno Morales¹⁰, María Martín López¹¹, Patricia Lopez Viejo¹², Virginia Ruiz-Esquide¹³, Julia Fernandez Melon¹⁴, David Castro-Corredor¹⁵, Ana Fernández-Ortiz¹⁶, Rafael Benito Melero-Gonzalez¹⁷, Carolina Díez Morrondo¹⁸, Desiree Palma¹⁹, Natividad del Val del Amo²⁰, Natalia Mena Vázquez²¹, Alicia García Dorta²², MARÍA JOSÉ PÉREZ GALÁN²³, MARINA SOLEDAD MORENO GARCIA²⁴ and Ricardo Blanco-Alonso²⁵, and on behalf of JAKi in Interstitial Lung Disease Associated with Rheumatoid Arthritis, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁴HOSPITAL NUESTRA SEÑORA DEL PRADO, TALAVERA DE LA REINA, Spain, ⁵Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, ⁶Basurto University Hospital, Bilbao, Spain, ⁷Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ⁸Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, ⁹Hospital General Río Carrión, Palencia, Spain, ¹⁰Hospital Universitario Santa Lucia Cartagena, Murcia, Murcia, Spain, ¹¹General University Hospital of Ciudad Real, Ciudad de México, Spain, ¹²Hospital Severo Ochoa, Madrid, Madrid, Spain, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴Hospital Son Espases, Palma, Spain, ¹⁵General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ¹⁶Hospital Universitario de Badajoz, Badajoz, Spain, ¹⁷CHU Ourense, O Carballino, Spain, ¹⁸Complejo Asistencial Universitario de Leon, Leon, ¹⁹Hospital Rafael Méndez, Lorca, Murcia, Spain, ²⁰Complejo Hospitalario de Navarra, Pamplona, Spain, ²¹IBIMA, Málaga, Andalucia, Spain, ²²Rheumatologist, La Laguna, Spain, ²³SERVICIO ANDALUZ DE SALUD, GRANADA, Andalucia, Spain, ²⁴Hospital Universitario Miguel Servet, GIJON, Asturias, Spain, ²⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
Abstract Number: 1548 • ACR Convergence 2024
Anifrolumab in Systemic Lupus Erythematosus. Spanish National Registry in a Real-world Setting
Carmen Secada Gómez¹, Vanesa Calvo-Rio², Miriam Retuerto Guerrero³, Judit Font⁴, Ivette Casafont-Sole⁵, Adrián Mayo-Juanatey⁶, Juan José Alegre Sancho⁶, Dalifer Freites Nuñez⁷, Cristina Hormigos⁸, Noemí Garrido-Puñal⁹, GUILLERMO GONZALEZ ARRIBAS¹⁰, Andrea García-Valle¹¹, Juan Roberto Miguelez Sanchez¹², Marta Ibáñez Martínez¹³, Fernando Lozano Morillo¹⁴, Ángel García Manzanares¹⁵, Sebastián Sandoval-Moreno¹⁶, Josefina Cortés-Hernández¹⁷, Desiree Palma¹⁸, Leticia Lojo Oliveira¹⁹, EVELIN CERVANTES PEREZ²⁰, PAZ COLLADO²¹, Cristina Arciniega Larios²², Luis Sala Icardo²³, Eztizen Labrador-Sánchez²⁴, Cilia Peralta Ginés²⁵, Nahia Plaza-Aulestia²⁶, Miguel Medina Malone²⁷, José Rosas-Gómez de Salazar²⁸, Montserrat Corteguera²⁹, Laura Cebrián¹⁹, Fred Anton Pages³⁰, JOSE RAMON LAMUA RIAZUELO³¹, maria Dolores Fábregas canales³², María José Alados Hernández³³, Marta Garijo Bufort³⁴, Anna Pamies Corts³⁵, Luis Sarabia De Ardanaz³⁶, Rodrigo Aguirre-del-Pino³⁷, José Ángel Cabezas Lefler³⁸, Álvaro Seijas-Lopez³⁷, Carmen Carrasco-Cubero³⁹, Ana López-Cerón Cofiño⁴⁰, Vera Ortiz-Santamaria⁴¹, Santos Castañeda⁴², María Laiño Piñeiro⁴³, Carmen Ordás Calvo⁴⁴, Celia Arconada Lopez⁴⁵, Carmen Bejerano⁴⁶ and Ricardo Blanco-Alonso⁴⁷, ANA URRUTICOECHEA⁴⁸, Blanca Garcia-Magallon⁴⁹, Ana Valeria Acosta Alfaro⁵⁰, Samuel Leal Rodriguez⁵¹, Marina Salido Olivares⁵² and Patricia Lavilla⁵³ ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Valdecilla Hospital, Santander, Cantabria, Spain, ³Complejo Asistencial Universitario de León, Leon, Spain, ⁴Hospital Germans Trias i Pujol, Barcelona, Spain, ⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁶Hospital Universitario Doctor Peset, Valencia, Spain, ⁷Hospital Clínico San Carlos. Madrid. Spain., Madrid, Spain, ⁸Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁹Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁰Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹¹Hospital General Río Carrión, Palencia, Spain, ¹²Hospital Universitario de Móstoles, Madrid, Spain, ¹³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹⁴Hospital Central de La Defensa Gómez Ulla, Madrid, Spain, ¹⁵Hospital Universitario de Torrevieja, Alicante, Spain, ¹⁶Hospital Universitario Vall d´Hebrón, Barcelona, Spain, ¹⁷Hospital Universitario Vall d´Hebrón Hospitals, Barcelona, ES, Barcelona, Spain, ¹⁸Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁹Hospital Universitario Infanta Leonor, Madrid, Spain, ²⁰Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, ²¹Hospital Universitario Severo Ochoa, MADRID, Spain, ²²Hospital de Mérida, Badajoz, Spain, ²³Hospital Universitario de Torrejón, Madrid, Spain, ²⁴Hospital General de La Rioja, Logroño, Spain, ²⁵Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁶Hospital Galdakao, Vizcaya, Spain, ²⁷Hospital Calahorra, La Rioja, Spain, ²⁸Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ²⁹ComplejoAsistencial de Ávila, Ávila, Spain, ³⁰Complejo Asistencial De Segovia, Segovia, Spain, ³¹Hospital Universitario del Henares, Madrid, Spain, ³²Hospital de Barbastro, Huesca, Spain, ³³Hospital Universitario Puerta del Mar, Cádiz, Spain, ³⁴Hospital de Sagunto, Valencia, Spain, ³⁵Hospital Verge de la Cinta, Tortosa, TARRAGONA, Spain, ³⁶Complejo Hospitalario de Jaén, Jaén, Spain, ³⁷Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁸Complejo Asistencial de Zamora, Zamora, Spain, ³⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁴⁰Hospital Santa Bárbara, Soria, Spain, ⁴¹Hospital General de Granollers, Barcelona, Spain, ⁴²Hospital Universitario de la Princesa, Madrid, Spain, ⁴³Hospital Universitario de Navarra, Pamplona, Spain, ⁴⁴Hospital Universitario de Cabueñes, Gijón, Spain, ⁴⁵Hospital Universitario Infanta Elena, Valdemoro, Madrid, Spain, ⁴⁶Hospital Universitario Marques de Valdecilla, Immunopathology group, IDIVAL, Santander, Cantabria, Spain, ⁴⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴⁸Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain, ⁴⁹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ⁵⁰Hospital Universitario Infanta Sofía, Madrid, Spain, ⁵¹HUP La Fe, Valencia, Spain, ⁵²Hospital Infanta Cristina, Parla, Spain, ⁵³Hospital General de Villalba, Collado Villalba, Spain
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1), thus blocking the biological activity of…
Abstract Number: 1681 • ACR Convergence 2024
Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study
Anna Zubrzycka-Sienkiewicz¹, Kamilla Klama², Martin Ullmann³, Corinne Petit-Frere³, Andras Illes³, Olga Menang³, Joëlle Monnet³ and Peter Baker³, ¹Reumatika - Centrum Reumatologil", NZOZ, Warszawa, Poland, ²Solumed Centrum Medyczne, Poznań, Poland, ³Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland
Background/Purpose: A therapy transition from the originator to a biosimilar offers significant advantages for patients by lowering medication costs and improving accessibility to treatments. MSB11456…
Abstract Number: 1804 • ACR Convergence 2024
Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development
Aleksandra Bylinska¹, Miles Smith¹, Rufei Lu¹, Benjamin Jones², Carla Guthridge¹, Matthew Caleb Marlin¹, Christian Wright³, Susan Macwana³, Wade DeJager³, Marci Beel³, Christopher Lessard¹, Cristina Arriens¹, Joan Merrill⁴, Judith James¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma State University, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: A loss of systemic self-tolerance to anti-nuclear autoantibodies (ANAs) is one of the main hallmarks of SLE. However, most healthy females with ANAs will…

« Previous Page
1
…
3
4
5
6
7
…
80
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].